This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on Web of Science (11)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Hugh Zachariae, MD; Peter Bjerring, MD
Department of Dermatology Marselisborg Hospital DK-8000 Aarhus, Denmark

Lene Heickendorff, MD
Department of Clinical Chemistry Aarhus Amtssygehus DK-8000 Aarhus, Denmark

Bjarne Møller, MD; Knut Wallevik, MD
Department of Clinical Immunology Skejby Sygehus University of Aarhus DK-8000 Aarhus, Denmark

Arch Dermatol. 1992;128(12):1651-1652.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

To the Editor.

—We have read with interest the article "Treatment of Systemic Sclerosis With Extracorporeal Photochemotherapy" by Rook and coworkers¹ in the March 1992 issue of the ARCHIVES. By no means do we question their results, but we find that we are obliged to express some words of caution, as it is our experience that patients with the severe progressive form of the disease may not all be sufficiently controlled by photopheresis alone. This, at least, applies to patients who have more pronounced symptoms from organs other than the skin.

For 5 to 8 months we have used photopheresis to treat eight patients with severe systemic sclerosis. We planned to treat all patients for at least 8 months, but, due to severe exacerbations, it was necessary to give additional immunosuppressive therapy to four patients. Two of these patients, together with another patient, wanted to discontinue photopheresis after 5 . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?